Kedrion and Kamada Announce FDA Approval of KedRAB Label Update, Confirming Safety and Effectiveness in Children

FORT LEE, N.J. and REHOVOT, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- Kedrion Biopharma and Kamada Ltd. (NASDAQ& TASE: KMDA), two leading biopharmaceutical companies specialized in plasma-derived protein therapeutics, announced today the U.S....
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news